Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Basilea Pharmaceutica AG    BSLN   CH0011432447


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Basilea reports acceptance for regulatory review of Pfizer's marketing authorization application for antifungal isavuconazole (Cresemba®) in China

share with twitter share with LinkedIn share with facebook
08/07/2020 | 02:15am EDT

Basel, Switzerland, August 07, 2020

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the marketing authorization  application (MAA) for the antifungal isavuconazole (Cresemba®) for the treatment of patients with mucormycosis, which was submitted by Basilea’s license partner Pfizer Inc. (NYSE: PFE, “Pfizer”), has been accepted for regulatory review by the Center for Drug Evaluation at the National Medical Products Administration (NMPA) of China.

David Veitch, Chief Executive Officer, said: “China is commercially a very important market for Cresemba, accounting for more than 15 percent of the global market for newer antifungals. We are therefore very pleased with the progress Pfizer is making in China, in order to address the unmet medical needs of patients suffering from invasive mold infections.”

In November 2017, Basilea and Pfizer extended their existing license agreement for Europe (excluding the Nordics), Russia, Turkey and Israel, to include China, including Hong Kong and Macao, and sixteen countries in the Asia Pacific region. Under the agreement with Pfizer, Basilea is still eligible for regulatory and sales milestone payments of up to approximately USD 630 million, in addition to receiving mid-teen royalties on sales.

Cresemba has been approved in more than 50 countries to date and is currently marketed in 45 countries, including the United States, most EU member states and several additional countries inside and outside of Europe. For the twelve-month period to the end of March 2020, total "in-market" sales of Cresemba amounted to USD 220 million, a more than 30 percent growth year-on-year.1

About Cresemba (isavuconazole)

Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. In the 27 European Union member states, as well as in Iceland, Liechtenstein, Norway and the U.K., isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.2 Cresemba is also approved in the United States and several additional countries in Europe and beyond.3 It has orphan drug designation in the U.S., Europe and Australia for its approved indications. Basilea has entered into several license and distribution agreements for isavuconazole covering the United States, Europe, China, Japan, Latin America, Asia-Pacific, the Middle East and North Africa region, Canada, Russia, Turkey and Israel.

About Basilea

Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.


This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Phone +41 61 606 1102
E-mail media_relations@basilea.com

This press release can be downloaded from www.basilea.com.


  1. IQVIA, March 2020. In-market sales reported as moving annual total (MAT) in U.S. Dollar corrected for currency fluctuations.
  2. European Public Assessment Report (EPAR) Cresemba: http://www.ema.europa.eu [Accessed: August 06, 2020]
  3. The registration status and approved indications may vary from country to country.


Primary Logo

© GlobeNewswire 2020

share with twitter share with LinkedIn share with facebook
10/26BASILEA PHARMACEUTICA : presents preclinical data on anti-angiogenic activity of..
10/26BASILEA PHARMACEUTICA : presents preclinical data on anti-angiogenic activity of..
10/26Basilea presents preclinical data on anti-angiogenic activity of derazantinib..
10/13BASILEA PHARMACEUTICA : reports interim results from phase 1/2 study FIDES-02 ex..
10/13BASILEA PHARMACEUTICA : reports interim results from phase 1/2 study FIDES-02 ex..
10/13Basilea reports interim results from phase 1/2 study FIDES-02 exploring deraz..
10/12BASILEA PHARMACEUTICA : reports pooled efficacy data for derazantinib in iCCA pa..
10/12BASILEA PHARMACEUTICA : reports pooled efficacy data for derazantinib in iCCA pa..
10/12Basilea reports pooled efficacy data for derazantinib in iCCA patients with F..
09/29GLOBAL MARKETS LIVE : Google wins Fitbit, Epic Games loses first court battle ag..
More news
Sales 2020 135 M 149 M 149 M
Net income 2020 -19,2 M -21,1 M -21,1 M
Net Debt 2020 110 M 121 M 121 M
P/E ratio 2020 -25,2x
Yield 2020 -
Capitalization 476 M 524 M 524 M
EV / Sales 2020 4,33x
EV / Sales 2021 3,95x
Nbr of Employees 225
Free-Float 88,3%
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 8
Average target price 91,38 CHF
Last Close Price 44,04 CHF
Spread / Highest target 218%
Spread / Average Target 107%
Spread / Lowest Target 18,1%
EPS Revisions
David Veitch Chief Executive Officer
Domenico Scala Chairman
Adesh Kaul Chief Financial Officer
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG62.63%47 039
SEAGEN INC.71.39%34 074
CELLTRION, INC.32.04%28 087
MODERNA, INC.259.10%27 716